Coexistence of a Novel NBAS-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient With LM and Response to Ensartinib

被引：0
|
作者：
Xu, X. [1 ,2 ,3 ]
Li, N. [1 ]
Fan, Y. [1 ,2 ]
机构：
[1] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[2] Chinese Acad Sci, Hangzhou, Peoples R China
[3] Zhejiang Chinese Med Univ, Hangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
ALK; non-small cell lung cancer (NSCLC); leptomeningeal metastases (LM);
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-09
引用
收藏
页码：S445 / S445
页数：1
相关论文
共 50 条
  • [1] Coexistence of a Novel PRKCB-ALK, EML4-ALK Double-Fusion in a Lung Adenocarcinoma Patient and Response to Crizotinib
    Luo, Jing
    Gu, Dejian
    Lu, Huasong
    Liu, Si
    Kong, Jinliang
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (12) : E266 - E268
  • [2] Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report
    Liang, Qi
    Xu, Huanhuan
    Liu, Yiqian
    Zhang, Weiming
    Sun, Chongqi
    Hu, Meng
    Zhu, Yizhi
    Tan, Shanyue
    Xu, Xian
    Wang, Sumeng
    Liu, Lingxiang
    [J]. LUNG CANCER, 2021, 162 : 86 - 89
  • [3] Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report
    Zeng, Qian
    Gao, Han
    Zhang, Longdan
    Qin, Shouming
    Gu, Yongyao
    Chen, Quanfang
    [J]. ANTI-CANCER DRUGS, 2021, 32 (08) : 890 - 893
  • [4] Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report
    Lin Zhu
    Jing Qin
    [J]. Discover Oncology, 14
  • [5] Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report
    Zhu, Lin
    Qin, Jing
    [J]. DISCOVER ONCOLOGY, 2023, 14 (01)
  • [6] Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
    Hong Tao
    Zhe Liu
    Jing Mu
    Fei Gai
    Zhan Huang
    Liang Shi
    [J]. Diagnostic Pathology, 17
  • [7] Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
    Tao, Hong
    Liu, Zhe
    Mu, Jing
    Gai, Fei
    Huang, Zhan
    Shi, Liang
    [J]. DIAGNOSTIC PATHOLOGY, 2022, 17 (01)
  • [8] Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report
    Wu, Xueqian
    Wang, Weiya
    Zou, Bingwen
    Li, Yanying
    Yang, Xiaojuan
    Liu, Ning
    Ma, Qizhi
    Zhang, Xiaoxuan
    Wang, Yongsheng
    Li, Dan
    [J]. THORACIC CANCER, 2020, 11 (06) : 1695 - 1698
  • [9] Identification of a Novel EML4-ALK Fusion Transcript in Lung Adenocarcinoma
    To, K.
    Tong, J. H. M.
    Law, P. P. Y.
    Chau, S. L.
    Lung, R. W. M.
    Yeung, S. F.
    Kang, W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S218 - S219
  • [10] Concomitance of a novel RMDN2-ALK fusion and an EML4-ALK fusion in a lung adenocarcinoma
    Jiang, Liqun
    Chen, Suping
    Stinnett, Victoria
    Haley, Lisa
    Morsberger, Laura
    Shane, Alison
    Hardy, Melanie
    Smith, Kirstin
    Gocke, Christopher D.
    Lin, Ming-Tseh
    Zhou, Ying S.
    [J]. CANCER GENETICS, 2021, 258 : 18 - 22
12345